**Business Performance:** Supriya Lifescience saw robust Q4 FY26 with Revenue up 50% YoY to Rs 276.53 Cr and PAT rising 47% YoY to Rs 74.23 Cr.

For FY26, Revenue grew 19% to Rs 827.87 Cr and PAT was up 11% to Rs 209.12 Cr.

Europe contributed significantly. **Growth Drivers or Strategy:** The company's backward-integrated model, accounting for 76% of FY26 revenue, underpins cost efficiency.

Focus on aggressive R&D for 3-4 new products annually and major capacity expansion, including new blocks and debottlenecking. **Recent Developments:** Successfully launched Cardio Vascular, ADHD, and Liquid Anesthetic products.

New vitamin block operational.

Further capacity expansion via an 'F' block and nasal line is in progress. **Key Financial Metrics:** FY26 EPS at INR 25.98. Healthy EBITDA and PAT margins show efficient operations. **Management Outlook:** Developing 30 finished dosage products.

Exploring CMO/CDMO in specialized areas.

Expanding API customer base in Japan, EU, US, with 6 EU dossier filings planned, indicating robust future growth.